Orbital Rhabdomyosarcoma: Relationship between DNA Ploidy, P53, Bcl-2, MDR-1 and Ki67 (MIB1) Expression and Clinical Behavior

Anticancer Research

Volumn 24, Issue 1, 2004, Pages 249-257

  Staibano, Stefania ^a,f   Franco, Renato ^a   Tranfa, Fausto ^a   Mezza, Ernesto ^a   Muzio, Lorenzo Lo ^b   Strianese, Diego ^a   Errico, Maria Elena ^a   Bufo, Pantaileo ^c   Ferrara, Gerardo ^d   Somma, Pasquale ^a   Mansueto, Gelsomina ^a   Immacolatagreco, ^e   Fiorillo, Amedeo ^f   Bonavolontà, Giulio ^a   De Rosa, Gaetano ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c UNIVERSITY OF FOGGIA   (Italy)

^d G RUMMO HOSPITAL   (Italy)

^e UNIVERSITY OF L'AQUILA   (Italy)

^f NONE

Author keywords

bcl2; DNA ploidy; Ki67 (MIB1); MDR 1; Orbital rhabdomyosarcoma; p53; Prognosis

Indexed keywords

DNA; KI 67 ANTIGEN; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN BCL 2; PROTEIN P53;

ADOLESCENT; ARTICLE; CANCER RECURRENCE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DNA DETERMINATION; ENDOREDUPLICATION; FEMALE; FEULGEN STAINING; FOLLOW UP; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; ONCOGENE; ORBIT CANCER; ORBIT RHABDOMYOSARCOMA; PLOIDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RHABDOMYOSARCOMA; TETRAPLOIDY;

DNA, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; ORBITAL NEOPLASMS; P-GLYCOPROTEIN; PLOIDIES; PROTO-ONCOGENE PROTEINS C-BCL-2; RHABDOMYOSARCOMA; RHABDOMYOSARCOMA, ALVEOLAR; RHABDOMYOSARCOMA, EMBRYONAL; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 10744221096     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Stout AP: Rhabdomyosarcoma of the skeletal muscles. Ann Surg 123: 447-472-796, 1946.
2. Maurer HM, Geham EA, Beltangady M et al: The Intergroup Rhabdomyosarcoma Study II. Cancer 71: 1904-1922, 1993.
3. Crist W, Gehan EA, Ragab AH et al: The third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 13: 610-630, 1995.
4. Newton WA, Soule EH, Hamoudi AB, Reiman HM, Shimada H, Beltangady M and Maurer H: Histopathology of childhood sarcomas, Intergroup Rhabdomyosarcoma Studies I and II: clinicopathologic correlation. J Clin Oncol 6: 67-95, 1988.
5. Palmer NG, Sachs N and Foulkes M: Histopathology and prognosis in rhabdomyosarcoma. Proc Am Soc Clin Oncol 1: 113-114, 1981.
6. Palmer NG, Sachs N and Foulkes M: Histopathology and prognosis in rhabdomyosarcoma (IRS I). Proc Am Soc Clin Oncol 1: 170, 1982.
7. Caillaud JM, Gerard-Merchant R, Marsden HB, Von Unnik AJ, Rodary C, Rey A and Flamant F: Histopathological classification of childhood rhabdomyosarcoma: a report from the International Society of Pediatric Oncology Pathology Panel. Med Pediatr Oncol 17: 391-400, 1989.
8. Dehner LP: Favorable vs unfavorable histologic appearance: the lexicon of pathologic grading of solid malignant neoplasm in children. Arch Pathol Lab Med 116: 817-820, 1992.
9. Schmidt D, Rainmann O, Trenner J and Herms D: Cellular differentiation and prognosis in embryonal rhabdomyosacoma. A report from the Cooperative Soft Tissue Sarcoma Study 1981. Virchows Arch 409: 183-194, 1986.
10. Horn RC and Enterline HT: Rhabdomyosarcoma: a clinicopathological study and classification of 39 cases. Cancer 11: 181-199, 1958.
11. Newton WA, Gehan EA and Webber BL: Classification of rhabdomyosarcoma and related sarcoma: pathologic aspects and proposal for a new classification- an Intergroup Rhabdomyosarcoma Study. Cancer 76: 1073-1085, 1995.
12. Cavazzana AO, Schmidt D, Ninfo V et al: Spindle cell rhabdomyosarcoma. A prognostically favorable variant of rhabdomyosarcoma. Am J Surg Pathol 16: 229-235, 1992.
13. Tsokos M, Webber BL and Parham DM: Rhabdomyosarcoma. A new classification scheme related to prognosis. Arch Pathol Lab Med 116: 847-56, 1992.
14. Hsu SM, Raine L and Fanger H: Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. Histochem Cytochem 29: 557-80, 1981.
15. Carrillo R, Candia A, Rodriguez-Peralto JL and Caz V: Prognostic significance of DNA ploidy and proliferative index (MIB-1 index) in gastrointestinal stromal tumor. Hum Pathol 28: 160-165, 1997.
16. Wormer RB: Problems and controversies in the management of childhood sarcomas. Br Med Bull 52: 826-843, 1996.
17. Maurer HM, Beltangady M, Gehan EA et al: The Intergroup Rhabdomyosarcoma Study I. a final report. Cancer 61: 209-220, 1988.
18. Sutow WW, Lindberg RD, Gehan EA, Ragab AH, Raney RB Jr, Ruymann F and Soule EH: Three years relapse-free survival rates in childhood rhabdomyosarcoma of the head and neck. Report from Intergroup Rhabdomyosarcoma Study. Cancer 49: 2217-2221, 1982.
19. Bonilla JA and Healy GB: Management of malignant head and neck tumors in children. Pd Clin North Am 36: 1443-1450, 1989.
20. Kraus DH, Saez NC, Gollamudi S et al: Pediatric rhabdomyosarcoma of the head and neck. Am J Surg 174: 556-560, 1997.
21. Kao GD, Willi SM and Goldwein J: The sequellae of chemoradiation therapy for head and neck cancer in children: managing impaired growth, devolopment, and other side effects. Med Ped Oncol 21: 60-66, 1993.
22. Smyth CM, Helmer MA, Dalla Pozza L and Rowe PB: Flow cytometric DNA analysis of frozen samples from children's solid tumors. Pathology 25: 388-93, 1993.
23. Molenaar WM, Dam Meiring A, Kamps WA and Cornelisse CJ: DNA-aneuploidy in rhabdomyosarcoma as compared with other sarcomas of childhood and adolescence. Hum Pathol 19: 573-579, 1988.
24. De Zen L, Sommaggio A, d'Amore ES et al: Clinical relevance of DNA ploidy and proliferative activity in childhood rabdomyosarcoma: a retrospective analysis of patients enrolled onto the Italian Cooperative Rabdomyosarcoma Study RMS88. J Clin Oncol 15: 1198-1205, 1997.
25. Barlogie B, Raber MN, Schumann J et al: Flow cytometry in clinical cancer research. Cancer Res 43: 3982-97, 1983.
26. Friedlander ML, Hedley DW and Taylor IW: Clinical and biological significance of aneuploidy in human tumors. J Clin Path 37: 961-74, 1984.
27. Quirke P and Dyson J: Flow cytometry: methodology and application in pathology. J Pathol 149: 79-87, 1986.
28. Look AT, Hayes FA, Nitschke R, McWilliams NB and Green AA: Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med 311: 231-5, 1984.
29. Pappo AS, Crist WM, Kuttesch J et al: Tumor cell DNA content predicts outcome in children and adolescents with clinical group III embryonal rhabdomyosarcoma. The Intergroup Rhabdomyosarcoma Study Committee of the Children Cancer Group and the Pediatric Oncology Group. J Clin Oncol 11: 1901-1905, 1993.
30. Wijnaendts L and van den Linden J: Prognostic importance of DNA flow cytometric variables in rhabdomyosarcoma. J Clin Pathol 46: 948-952, 1993.
31. Niggli FK, Powell JE, Parkes SE, Ward K, Rafat F, Mann JR and Stevens MC: DNA ploidy and proliferaive activity (S-phase) in childhood soft tissue sarcomas: their value as prognostic indicators. Br J Cancer 69: 1106-1110, 1994.
32. Wurl P, Taubert H, Bache M et al: Frequent occurrence of p53 mutations in rhabdomyosarcoma and leiomyosarcoma, but not in fibrosarcoma and malignant neural tumors. Int J Cancer 69: 313-323, 1996.
33. Cordon-Cardo C, Latres E, Drobjak M et al: Molecular abnormalities of mdm2 and p53 genes in adult soft-tissue sarcomas. Cancer Res 54: 794-799, 1994.
34. Finlay CA, Hinds, PW and Levine AJ: The p53 protooncogene can act as a suppressor of transformation. Cell 57: 1083-1093, 1989.
35. Gannon JV, Greaves R, Iggo R and Lane DP: Activating mutations in p53 produce a common conformational event. A monoclonal antibody specific for the mutant form. EMBO J 9: 1595-1602, 1990.
36. Levine AJ, Momand J and Finlay CA: The p53 tumour suppressor gene. Nature 351: 453-456, 1991.
37. Jacobson MD, Burne JF, King MP, Miyashita T, Reed JC and Raff MC: Bcl-2 blocks apoptosis in cells lacking mitochondrial DNA. Nature 361: 365-369, 1993.
38. Myashita T, Krajewski S, Krajewska M et al: Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9: 1799-1805, 1994.
39. Delia D, Aiello A, Soligo D et al: Bcl-2 proto-oncogene expression in normal and neoplastic human myeloid cells. Blood 79: 1291-1298, 1992.
40. Vaux DL, Cory S and Adams JM: Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335: 440-442, 1988.
41. Hockenbery DM, Zutter M, Hickey W, Nahm M and Korsmeyer SJ: Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 88: 6961-6965, 1991.